Baclofen

Baclofen 10 mg

Manufacturer:GlaxoSmithKline

Product Name:Baclofen 10 mg/10 mg film-coated tablets

Product Description:Baclofen 10 mg/10 mg film-coated tablets is a muscle relaxant that is used to treat muscle spasticity or spasticity that is not relieved by rest. The active ingredient in this product is baclofen. Baclofen can be found in the following strengths: 10 mg, 20 mg, 40 mg, and 60 mg. These are the strengths prescribed by a doctor, depending on the patient’s condition. A doctor should prescribe baclofen when baclofen is prescribed for an adult patient. However, some patients have reported side effects, so this product is not recommended to treat this patient’s condition. Baclofen can cause side effects, although not everybody experiences them. Most side effects are mild, such as headache, upset stomach, and stomach cramps. In some patients, it can be a long-term side effect. If you experience any side effects, contact your doctor right away. Talk to your doctor about the risks and benefits of this product. If you have any questions, please contact your doctor. For more information about this product, please see the product label, which is also available on our website.

Uses of Baclofen

Baclofen is used to treat muscle spasms caused due to cerebral palsy, multiple sclerosis, stroke or due to any other nerve or spinal cord disorders.

Therapeutic Category

Baclofen: Muscle Relaxants

How Baclofen works

Baclofen is a muscle relaxant. It acts by increasing the effects of certain chemical messengers (such as GABA) in the spinal cord that induces muscle relaxation. As a result, it prevents muscle twitching, relieves pain caused due to muscle spasms and improves muscle movement.

Common side effects of Baclofen

• nausea, vomiting
• tiredness, sleepiness
• weak limbs, muscle pain
• constipation, diarrhoea, dry mouth
• lack of sleep, nightmares
• confusion, hallucination
• breathing difficulties
• vision problems
• urge to pass urine
• feeling unsteady or shaky
• feeling faint due to low blood pressure
• skin rash, sweating

When to consult your doctor

Consult your doctor:

• in case of accidental overdosage
• if you experience feeling extremely depressed with thoughts of harming or killing themselves (suicidal thoughts)
• if you experience signs of severe allergic reactions (such as skin rash, itching, swelling of the face, lips, throat or tongue causing difficulty in breathing or swallowing)
• if you experience uncontrollable muscle spasms affecting the eyes, head, neck or body
• if you experience behavioural changes (such as aggression, excitement, confusion, restlessness, agitation, irritability, rages, hallucinations, nightmares)
• if you experience fainting or seizures (fits)

Health Tips for Baclofen

• Avoid alcohol consumption as it may increase the sedative effects of Baclofen, leading to increased drowsiness and impairment
• Drink an adequate amount of water to help prevent constipation
• Follow a healthy lifestyle by eating a balanced diet, engage in regular physical activity and get sufficient sleep to support the recovery and minimize the impact of muscle spasms

Read more about>Health Tips

Take in the dose and duration as advised by your doctor. Do not take more than 1 tablet in a day, or any dose that is higher than that.

Side effects:

• feeling shaky
• blistering, tingling, swelling of the hands, feet, lips, eyes, mouth, neck or back
• medicines for anxiety or muscle pain: panic, headache, nausea, flushing, abnormal vision, dizziness, swollen glands, diarrhoea, typhus or bacterial infection
• medicines for conditions: blood circulation drugs such as::

It is also important to look at any side effects that you are experiencing.

Introduction

The purpose of this study was to investigate the prevalence of muscle spasticity in the population with comorbidity of cerebral palsy (CP), and to determine its prevalence rate in the general population. This study was a retrospective study carried out from January 2005 to January 2013 in the outpatient department of the Division of Geriatrics and Neurosurgery at the University Hospital of Vara de los Banos de La Guyana. Patients with CP were divided into two groups according to the number of CP symptoms (Group 1-1.1). Group 1.1 is the most frequent CP, with a prevalence of 0.3%. Group 1.1 is less frequent than Group 1.1, but this percentage may increase due to a number of patients who have a history of CP in the past. We also conducted a cross-sectional study to determine the prevalence of CP in the general population with comorbidity of CP and to investigate the prevalence of CP in the population with CP. We also aimed to identify a possible association between the prevalence of CP and the prevalence of CP in the general population with comorbidity of CP.

Methods

This was a retrospective study carried out between January 2005 and January 2013 in the outpatient department of the Division of Geriatrics and Neurosurgery at the University Hospital of Vara de los Banos de La Guyana. The Department of Geriatrics and Neurosurgery at the University Hospital of Vara de los Banos de La Guyana was the clinical setting and was composed of a combination of medical, rehabilitation and psychotherapeutic departments. The outpatient departments of the Division of Geriatrics and Neurosurgery at the University Hospital of Vara de los Banos de La Guyana and the Department of Geriatrics and Neurosurgery at the Vara de los Banos de La Guyana were selected as the study groups according to the characteristics of patients with CP (Group 1.1). The patients in the Group 1.1 included patients who had a history of CP (Group 1.1.1). The patients in the Group 1.1 were recruited from the outpatient department of the Division of Geriatrics and Neurosurgery at the University Hospital of Vara de los Banos de La Guyana and the Department of Geriatrics and Neurosurgery at the Vara de los Banos de La Guyana.

Study population

Patients with CP were divided into two groups according to the number of CP symptoms (Group 1.1 and Group 1.1.2). The patients in the Group 1.1 were divided into two groups according to the number of CP symptoms (Group 1.1.1) or the presence of CP in the last 3 months of the period of the period of CP (Group 1.1.3).

Patients with CP and the presence of CP in the last 3 months of the period of CP

We also conducted a cross-sectional study to determine the prevalence of CP and to determine the prevalence of CP in the general population with comorbidity of CP and to investigate the prevalence of CP in the population with CP.

Ethical statement

This study was approved by the Institutional Ethical Committee of Vara de los Banos de La Guyana, and the Ethics Committee of the Hospital Vara de los Banos de La Guyana (Approval Number: H01-1536, No. H06-0122). All patients provided written informed consent.

Patient selection

A total of 553 patients with CP were selected from the department of Geriatrics and Neurosurgery in the Vara de los Banos de La Guyana and the Vara de los Banos de La Guyana. These patients were recruited from the outpatient department of the Vara de los Banos de La Guyana. The inclusion criteria were patients who met the following criteria: 1.1.1.1; 2.1.1.2, or 1.2.1.3. The patients had a history of CP or the presence of CP in the last 3 months of the period of CP. We excluded patients with a diagnosis of CP who were suffering from cerebral palsy. Patients who had received a prescription of baclofen or a muscle relaxant for the past six months or a patient who was taking anti-depressant medication for the past 6 months were excluded. In the period of CP, patients were divided into two groups according to the presence of CP (Group 1.1.1 and Group 1.1.2).

Aaclofen is a muscle relaxant that works to relieve symptoms of spasticity caused by cerebral palsy, muscle spasms, and others. It is used in the treatment of cerebral palsy and spasticity associated with cerebral palsy, including:

• The treatment of spasticity is based on the principle of maintaining normal muscle tone. Spasticity can result from various causes including:

• Muscle spasms

• Spasticity is caused by a variety of other disorders such as spinal injury, cerebral palsy, and other conditions.

• Treatments for spasticity have been developed to reduce muscular pain, stiffness, and cramps associated with this disorder.

Aaclofen is not suitable for people with certain types of cerebral palsy. Other treatments, such as surgery and rehabilitation, can be effective in managing these symptoms.

How It Works

In a muscle relaxant, an enzyme that breaks down certain chemicals in muscle cells causes relaxation of the muscle. Baclofen works by inhibiting muscle contractions, which allows the muscles to relax and contract more effectively.

Aaclofen is available as tablets (baclofen and metaclofen) and oral suspension. You can take it with or without food. It should be taken at least 2 hours before or after eating.

Benefits

Aaclofen is a muscle relaxant that acts directly on the muscle cells and spinal cord, helping them relax and contract.

Baclofen is an agonist and antagonist of the GABA (gamma-aminobutyric acid) receptor in the brain. Baclofen is thought to inhibit excitatory neurotransmission resulting in decreased excitatory postsynaptic cleft, leading to dilation of synaptic vesicles. Baclofen is available as oral tablets, capsules, and solution. The tablets have a molecular weight of about 270.6, the capsule has a molecular weight of about 177.7, the solution has a molecular weight of about 175, the suspension has a molecular weight of about 200.6. Baclofen is rapidly absorbed with peak plasma concentrations occurring in the 1-2 hours following administration. Peak plasma concentrations occur within 1 hour and reach steady-state concentrations up to 4 hours. Baclofen is rapidly and completely absorbed. Peak plasma concentrations are usually within 1 hour. The elimination half-life of baclofen is about 2 hours. The bioavailability of baclofen is 100%. The pharmacokinetics of baclofen were evaluated in healthy subjects. The mean protein binding was 0.9 +/- 0.4 binding units/mL for baclofen and 4.5 +/- 0.7 binding units/mL for baclofen plus dibutych. The mean AUC0-t/t was 0.7 +/- 0.3 (range, 0.5-1.3) for baclofen plus dibutych plus baclofen plus placebo. The mean AUC0-t/t for baclofen plus baclofen plus placebo was 4.0 +/- 0.3 (range, 1.4-11.6) for baclofen plus placebo plus dibutych plus placebo. There was no significant difference in plasma baclofen concentrations between the baclofen plus placebo (17.1 +/- 6.6 mcg/mL) and the placebo group (10.0 +/- 4.2 mcg/mL) (P = NS). The mean elimination half-life of baclofen was 2.1 hours and the AUC0-t/t for baclofen was 3.8 +/- 1.9 hours for placebo plus dibutych plus placebo and 3.7 +/- 1.2 hours for placebo plus baclofen plus placebo (P = NS). Baclofen is a safe and well-tolerated drug. The pharmacokinetics of baclofen are similar to that of other drugs with similar side effects. The drug should be used with caution and under the supervision of a doctor.

Baclofen oral tablets

The clinical pharmacokinetic parameters of baclofen oral tablets have been evaluated in healthy volunteers. Mean AUC0-t/t for baclofen, t1/2, AUC0-t/t for baclofen plus dibutych plus placebo, and AUC0-t/t for baclofen plus dibutych plus placebo plus placebo were determined using a dose-response model. Mean BCRP/CRP ratio was used to assess the clinical pharmacokinetic parameters. Mean AUC0-t/t and AUC0-t/t were determined to be 2.4 +/- 0.8 and 2.2 +/- 0.5, respectively. The mean AUC0-t/t for baclofen plus dibutych plus placebo was 3.7 +/- 1.1 and 3.5 +/- 1.2, respectively. Mean AUC0-t/t for baclofen plus baclofen plus placebo was 5.5 +/- 3.1 and 6.6 +/- 2.1, respectively. The mean AUC0-t/t for baclofen plus placebo plus placebo was 6.8 +/- 3.4 and 9.0 +/- 4.3, respectively. The mean AUC0-t/t for baclofen plus placebo plus placebo was 4.6 +/- 2.1 and 9.0 +/- 2.1, respectively. The mean AUC0-t/t for baclofen plus placebo was 15.4 +/- 4.4 and 13.6 +/- 2.0, respectively.

The following PK parameters for baclofen oral tablets were determined in healthy volunteers using a dose-response model. Mean AUC0-t/t for baclofen and AUC0-t/t for baclofen plus dibutych plus placebo were determined using a dose-response model. Mean BCRP/CRP ratio was determined using a dose-response model.

Dalhoff JM, Houghton J, Kowalowski K, Fisch P, et al. The effects of baclofen, a muscle relaxant, and biv atenolol on the renoprotective effect of baclofen, naloxone, and the effect of naloxone on the renoprotective effect of naloxone. Int J Clin Pharmacol. 2016;7(3):611–23.

Dalhoff JM, Kowalowski K, Fisch P, Houghton J, et al. Effects of baclofen, naloxone, and biv atenolol on renal blood flow and renal function in rats. J Toxicol. 2017;33(3):621–8.

Grosser L, Schmiedler K, Fisch P, Houghton J, et al. Effects of baclofen, naloxone, and biv on renal blood flow and renal function. J Am Soc Nephrol. 2011;16(5):853–60.

Kowalowski K, Fisch P, Houghton J, Fisch P, et al. Effects of baclofen, naloxone, and biv on renal function and renal blood flow in rats. 2013;16(3):813–25.

Effects of baclofen, naloxone, and biv on renal blood flow and renal function in rats. 2014;16(3):847–54.

2015;35(4):1182–96.

Kowalowski K, Fisch P, Houghton J, Houghton J, et al. 2016;31(5):1029–37.

2017;32(6):1259–64.

Bassmann H, Wockhardt K, Wockhardt P, Kowalowski K. 2016;31(5):1298–200.

Wockhardt K, Kowalowski K, Houghton J, Houghton J, et al.

2017;32(6):1294–103.

Wockhardt K, Kowalowski K, Houghton J, Kowalowski K, et al. 2017;32(6):1295–7.